Good morning, everyone, and welcome to Vaxcyte's 2026 Annual Meeting of Stockholders. I'd now like to introduce your first presenter, Carlos Paya, Chairman of the Board. Dr. Paya, the floor is now yours. Thank you, and hello, ladies and gentlemen. Let the meeting please come to order. I welcome all of you to Vaxcyte's 2026 Annual Meeting of Stockholders. I am Carlos Paya, Chairman of the Board, and I will be presiding at this meeting. Also present at the meeting today are the other members of our board, including Grant Pickering, our CEO, Board Member, and Co-Founder, as well as Andrew Guggenhime, our President and CFO, and Mikhail Eydelman, our General Counsel. Mr. Eydelman will act as secretary of the meeting. Mike Barbera of First Coast Results has been appointed to act as the Inspector of Election, and representatives from Deloitte & Touche are also present. The polls are now open if you wish to vote via the Internet. If you previously voted by proxy, you do not need to vote today unless you wish to change your vote. To conduct an orderly meeting, we ask that stockholders who desire to ask a question or make a statement about a proposal submit their question or statement through the virtual meeting website. We ask that you restrict your remarks to the item of the agenda that is before us. Questions and statements of a general nature will be held until after the formal business of the meeting has concluded. The secretary has delivered an affidavit of mailing establishing that notice of this meeting was duly given. A copy of the notice of the meeting and the affidavit of mailing will be incorporated into the minutes of this meeting. All stockholders of record at the close of business on April 20, 2026, are entitled to vote at the annual meeting. Mr. Barbera has taken and subscribed the customary oath of office to execute his duties as Inspector of Election. We will file this oath with the records of the meeting. His function is to decide upon the qualifications of voters, accept their votes, and when balloting on all matters is completed, to tally the final votes. Our first order of business is to determine whether the shares represented at the meeting, either in person or by proxy, are sufficient to constitute a quorum for the purpose of transacting business. Mr. Eydelman, do you have a report? Yes. On the record date, there were 144,387,225 shares of common stock of the company outstanding and entitled to vote at this meeting. We are informed by Mr. Barbera that there are represented, in person or by proxy, 137,368,483 shares of common stock, or approximately 95.13% of all the shares entitled to vote at this meeting. Thank you. Because holders of a majority of the shares entitled to vote at this meeting are present in person or by proxy, I declare this meeting to be duly convened for purposes of transacting such business as may properly come before it. The next order of business is to provide a description of the proposals to be voted on at today's meeting. The first proposal before the stockholders of the company is the election of three Class III directors to serve until 2029 Annual Meeting of Stockholders and until their successors have been duly elected and qualified, or if sooner, until the director's death, resignation, or removal. The board recommends a vote for the election of the following persons as directors of the company: Olivier Brandicourt, Halley Gilbert, and Grant Pickering. The second proposal before the stockholders is ratification of the appointment of Deloitte & Touche LLP as the company's independent registered public accounting firm for the fiscal year ending December 31st, 2026. The board recommends a vote for the ratification of the appointment of Deloitte & Touche. The third proposal before the stockholders is the advisory vote on the executive compensation of the company's named executive officers as described in the proxy statement. The stockholders have been asked to vote on an advisory basis on the following resolution. Resolved that the company's stockholders hereby approve on a non-binding advisory basis the compensation of the company's named executive officers as disclosed in the company's proxy statement for the 2026 Annual Meeting of Stockholders pursuant to the compensation disclosure rules of the SEC, including the compensation discussion and analysis, the compensation tables, and the accompanying narrative. The board recommends a vote for the approval of the non-binding resolution on named executive officer compensation. That was the final proposal for today's meeting. We will now review if there are any questions submitted about the proposals before we close the polls. As a reminder, we will only review and answer questions at this time that pertain to the proposals. Mr. Secretary, are there any questions or discussion related to the proposals? There are no questions in the queue. Dr. Paya, we may now return to the agenda. Thank you. I hereby declare the polls closed. Will the Secretary please report the results of the voting? The preliminary report of the Inspector of Election indicates that all proposals, as recommended by the board, have passed. Please note that we will file a Form 8-K with the SEC disclosing the results. Thank you. This concludes the business matters to be brought before the 2026 Annual Meeting of Stockholders. The meeting is now adjourned. We will now have a brief question and answer period. There are no questions in the queue. Thank you. Our question and answer period is now closed. On behalf of the board and management of Vaxcyte, thank you so much for attending today's meeting. The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.